10.1002/anie.201807322
Angewandte Chemie International Edition
COMMUNICATION
convergent couplings between two complex coupling
partners and was exemplified by synthesizing a novel
kinase inhibitor. Simple protocols, readily available
reagents and applicability to pharmacogically-relevant
molecules make this approach useful for medicinal
chemists.
H
N
H
N
Sorafenib – tyrosine kinase inhibitor
O
O
N
Cl
– renal cell, hepatocellular and
thyroid carcinoma treatment
CF3
– ‘type II’ binding mode
O
pyridine binds
to ATP allosteric
binding site
– heteroaryl ether synthesized via SNAr
NHMe
Acknowledgements
Synthesis of a novel kinase inhibitor derivative
H
N
H
N
PPh3
We acknowledge support by start-up funds from Colorado State
University and from The National Institutes of Health under award
number R01 GM124094.
O
OTf
HO
Cl
3
CF3
N
CO2Me
(halide not commercial)
NaH, DME
15-Crown-5,
0 ºC to 80 ºC
Keywords: heteroatom coupling • pyridines • phosphonium salts
H
N
H
N
• late-stage • kinase inhibitors
O
O
N
Cl
[1]
P. Wu, T. E. Nielsen, M. H. Clausen, Trends Pharmacol. Sci. 2015, 36,
422.
CF3
[2]
[3]
L. N. Johnson, Q. Rev. Biophys. 2009, 42, 1.
2bq, 40%
CO2Me
For examples of SNAr reactions see: a) K. Walsh, H. F. Sneddon, C. J.
Moody, RSC Adv. 2014, 4, 28072; b) J. Liu, M. J. Robins, J. Am. Chem.
Soc. 2007, 129, 5962.
Scheme 2. Phosphonium coupling reactions to make novel kinase inhibitors.
[4]
For reviews see: a) D. S. Surry, S. L. Buchwald, Angew. Chem. Int. Ed.
2008, 47, 6338; b) P. Ruiz-Castillo, S. L. Buchwald, Chem. Rev. 2016,
116, 12564; c) J. F. Hartwig, Acc. Chem. Res. 2008, 41, 1534; d) M.
Kienle, S. R. Dubbaka, K. Brade, P. Knochel, Eur. J. Org. Chem. 2007,
2007, 4166; e) B. M. Rosen, K. W. Quasdorf, D. A. Wilson, N. Zhang, A.-
M. Resmerita, N. K. Garg, V. Percec, Chem. Rev. 2011, 111, 1346; f) S.
V. Ley, A. W. Thomas, Angew. Chem. Int. Ed. 2003, 42, 5400; g) S.
Bhunia, G. G. Pawar, S. V. Kumar, Y. Jiang, D. Ma, Angew. Chem. Int.
Ed. 2017, 56, 16136; h) C.-F. Lee, Y.-C. Liu, S. S. Badsara, Chem. Asian.
J. 2014, 9, 706.
cancer drug abiraterone acetate (2bm and 2bn). Site-
selective processes were again exploited to make
functionalized derivatives of etoricoxib and gleevec (2bo
and 2bp) with the latter isolated as a 10:1 mixture of
regioisomers.
As a final demonstration of the utility of the coupling
process, we examined a convergent coupling reaction to
make a novel kinase inhibitor derivative that would be
challenging to access via conventional metal-catalyzed
cross coupling or SNAr reactions (Scheme 2). Sorafenib is
a marketed tyrosine kinase inhibitor that contains a
pyridine–O–aryl linkage (Scheme 2); in ‘type II binding’
the pyridine moiety occupies an allosteric pocket and
competes with ATP.[1,2,17,18] We envisioned a convergent
disconnection where a pyridylphosphonium salt could
react with phenol 3 that includes the diaryl urea moiety.
Scheme 2 shows a representative pyridine phosphonium
salt where the corresponding halide would be challenging
to prepare; coupling to phenol 3 proceeds in reasonable
yield to form 2bq and demonstrates that novel kinase
inhibitors can be rapidly synthesized via this approach.
[5]
For examples of recent light-driven processes see: a) E. B. Corcoran, M.
T. Pirnot, S. Lin, S. D. Dreher, D. A. DiRocco, I. W. Davies, S. L.
Buchwald, David, W. C. MacMillan, Science 2016, 353, 279; b) S. E.
Creutz, K. J. Lotito, G. C. Fu, J. C. Peters, Science 2012, 338, 647; c)
C.-H. Lim, M. Kudisch, B. Liu, G. M. Miyake, J. Am. Chem. Soc. 2018,
140, 7667; d) D. T. Ziegler, J. Choi, J. M. Muñoz-Molina, A. C. Bissember,
J. C. Peters, G. C. Fu, J. Am. Chem. Soc. 2013, 135, 13107; e) C. Uyeda,
Y. Tan, G. C. Fu, J. C. Peters, J. Am. Chem. Soc. 2013, 135, 9548; f) Y.
Tan, J. M. Muñoz-Molina, G. C. Fu, J. C. Peters, Chem. Sci. 2014, 5,
2831.
[6]
[7]
J. P. Finer, Ligand Coupling Reactions with Heteroaromatic Compounds,
Tetrahedron Organic Chemistry Series, Pergamon Press, Oxford, Vol.
18. Chap. 4.
A similar strategy involving stoichiometric palladium complexes has been
exploited for bioconjugation and fluorination reactions, see: a) E. V.
Vinogradova, C. Zhang, A. M. Spokoyny, B. L. Pentelute, S. L. Buchwald,
Nature 2015, 526, 687; b) E. Lee, A. S. Kamlet, D. C. Powers, C. N.
Neumann, G. B. Boursalian, T. Furuya, D. C. Choi, J. M. Hooker, T. Ritter,
Science 2011, 334, 639.
In summary, we have shown that pyridine and diazine
phosphonium salts can serve as coupling partners with
seven classes of aromatic heteronucleophiles. Advantages
of this strategy over conventional approaches include a
distinct scope of azine coupling partners, a simplified
mechanism and a narrow range of reaction conditions.
Applying this method to complex drug-like molecules is
also feasible and enables medicinal chemistry to rapidly
access valuable analogues. The method also enables
[8]
[9]
D. C. Blakemore, L. Castro, I. Churcher, D. C. Rees, A. W. Thomas, D.
M. Wilson, A. Wood, Nat. Chem. 2018, 10, 383.
a) M. C. Hilton, R. D. Dolewski, A. McNally, J. Am. Chem. Soc. 2016,
138, 13806; b) E. Anders, F. Markus, Tetrahedron Lett. 1987, 28, 2675;
c) E. Anders, F. Markus, Chem. Ber. 1989, 122, 113; d) E. Anders, F.
Markus, Chem. Ber. 1989, 122, 119; e) M. Haas, H. Goerls, E. Anders,
E. Synthesis 1998, 195.
[10] a) X. Zhang, A. McNally, Angew. Chem. Int. Ed. 2017, 56, 9833; b) J. L.
Koniarczyk, D. Hesk, A. Overgard, I. W. Davies, A. McNally, J. Am. Chem.
Soc. 2018, 140, 1990; c) Anderson, R. G.; Jett, B. M.; McNally, A.
Tetrahedron. 2018, 74, 3129; d) C. Patel, M. L. Mohnike, M. C. Hilton; A.
This article is protected by copyright. All rights reserved.